Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multicenter phase II study of spiroplatin.

B C Tanis1, J B Vermorken, W W ten Bokkel Huinink

  • 1Free University Hospital, Amsterdam, The Netherlands.

Oncology
|January 1, 1992
PubMed
Summary

Spiroplatin showed limited efficacy in treating various solid tumors and caused significant, unpredictable renal toxicity. Due to severe side effects and poor response, this clinical trial was terminated early.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.

Leukemia·2024
Same author

Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer.

European journal of cancer (Oxford, England : 1990)·2017
Same author

Complicated postoperative recovery increases omission, delay and discontinuation of adjuvant chemotherapy in patients with Stage III colon cancer.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2013
Same author

Prognostic value of geriatric assessment in older patients with advanced breast cancer receiving chemotherapy.

Breast (Edinburgh, Scotland)·2013
Same author

Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients.

Sarcoma·2007

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Spiroplatin is a platinum-based chemotherapy agent.
  • Platinum compounds are widely used in cancer treatment.
  • Nephrotoxicity is a significant concern with platinum-based drugs.

Purpose of the Study:

  • To evaluate the efficacy and safety of spiroplatin in patients with advanced solid tumors.
  • To assess the incidence and severity of side effects, particularly renal toxicity.

Main Methods:

  • A multicenter phase II clinical study.
  • 64 patients with nine different solid tumors received spiroplatin at 30 mg/m2 every 3 weeks.
  • Patients' responses and adverse events, including renal function, were monitored.

Related Experiment Videos

Main Results:

  • Limited antitumor activity was observed, with only 3 patients responding (renal cell carcinoma, ovarian carcinoma, malignant melanoma).
  • Significant renal toxicity occurred in both patients with and without prior cisplatin exposure.
  • Nausea, vomiting, myelosuppression, and renal toxicity were the most frequent side effects.

Conclusions:

  • Spiroplatin demonstrated insufficient antitumor activity.
  • The drug exhibited severe and unpredictable renal toxicity, which was not mitigated by hydration.
  • The study was prematurely stopped due to poor efficacy and unacceptable toxicity.